a375 female (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
a375 female
A375 Female, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5079 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a375 female/product/ATCC
Average 99 stars, based on 5079 article reviews
A375 Female, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5079 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a375 female/product/ATCC
Average 99 stars, based on 5079 article reviews
a375 female - by Bioz Stars,
2026-05
99/100 stars
Images
1) Product Images from "Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma"
Article Title: Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma
Journal: Cell Death & Disease
doi: 10.1038/s41419-026-08578-4
Figure Legend Snippet: A Colony formation assay (CFA) quantification of A375VR cells treated with DMSO or ranolazine (RANO) in presence of ferrostatin-1 (ferro) or liproxstatin-1 (lipro) or DMSO (D). ( n = 3, Mean ± SEM, Holm-Sidák test of one-way ANOVA. * p -value ≤ 0.05; ** p -value ≤ 0.01; **** p -value ≤ 0.0001). B Total levels (integrated peak areas, arbitrary units – a.u.) of indicated fatty acids in A375 parental versus resistant A375VR cells. ( n = 4, Mean ± SD, two-tailed unpaired t -test. ** p -value ≤ 0.01; **** p -value ≤ 0.0001). C , D Heatmap of the indicated ( C ) phosphatidylethanolamine (PE) or ( D ) phosphatidylcholine (PC) levels in parental A375 or A375VR cells. Peak area values were normalised to the average of the respective parental values. Only lipids with a median fold change between parental and A375VR cells of p ≤ 0.05 ( n = 4, two-tailed unpaired t -test) are shown. E Heatmap showing MAGIC expression z-scores of ferroptosis regulator genes, with cells ordered using hierarchical clustering applied both within and between Seurat clusters, and colour-coded by parental or VR sample identity. F Basal lipid peroxidation in A375 and A375VR cells assessed through Alexa Fluor™ 488 fluorescence imaging ( n = 6, Mean ± SEM, two-tailed unpaired t -test. ** p -value ≤ 0.01). G Total levels (integrated peak areas) of glutathione (GSH) in A375 versus A375VR cells ( n = 4, Mean ± SEM, two-tailed unpaired t -test. **** p -value ≤ 0.0001). H Uniform Manifold Approximation and Projection (UMAP) visualisation of parental A375 and A375VR cells coloured by the expression of ferroptosis regulators shown in ( E ) or the expression of the Tsoi undifferentiated (UD) state . I Discrete expression of the Tsoi UD state as well as of FAO regulators based on the 90th percentile of signature scores across the whole dataset. J Biological functions enriched (based on hypergeometric tests) in the top 200 most overexpressed genes of FAO-high cells as defined ( I ) compared to the remaining cells. The dashed line indicates p = 0.05.
Techniques Used: Colony Assay, Two Tailed Test, Expressing, Fluorescence, Imaging
Figure Legend Snippet: A Growth curves of A375 tumours from mice treated with BRAFi (25 mg/kg, daily) and RANO (50 mg/kg, daily) as described . Tumours had been allowed to grow until resistance against BRAFi (VR, n = 8) or against BRAFi + RANO (VR-RAN n-R, n = 4) was established. Tumours that still responded to BRAFi + RANO were classified as VR-RAN R ( n = 4). B Tumour volume at endpoint of the experiment. (Mean ± SEM, Tukey test of one-way ANOVA. ** p -value ≤ 0.01). C RT-qPCR analysis of the indicated genes in A375 tumours from mice treated as indicated. Data are triplicates from n = 8 tumours for vehicle (veh) or BRAFi (VR), and n = 4 tumours for RANO responder (R) or RANO non-responders (n-R). (Mean ± SEM, uncorrected Fisher’s LSD test of one-way ANOVA. * p -value ≤ 0.05; ** p -value ≤ 0.01; **** p -value ≤ 0.0001).
Techniques Used: Quantitative RT-PCR
Figure Legend Snippet: A Heatmap showing MAGIC expression z-scores of ferroptosis regulator genes, with cells ordered using hierarchical clustering applied both within and between Seurat clusters, and colour-coded by VR or VR_RANO sample identity. B Basal lipid peroxidation in A375, VR and VR_RANO cells assessed through Alexa Fluor™ 488 fluorescence imaging ( n = 8, Mean ± SEM, Tukey test of one-way ANOVA. * p -value ≤ 0.05; **** p -value ≤ 0.0001). C UMAP plot for VR and VR_RANO cells coloured by the expression of ferroptosis regulators, FAO regulators and GPX4. D Total levels (integrated peak areas) of glutathione (GSH) in VR versus VR-RANO cells ( n = 4, Mean ± SEM, two-tailed unpaired t -test. p -value = 0,0542). E Dose response curve for RSL3 in VR and VR_RANO cells. F , G CFA quantification of VR and VR_RANO cells treated with the indicated concentrations of ( F ) RSL3 and ( G ) erastin. ( n = 6, Mean ± SEM, Holm-Sidák test of one-way ANOVA. * p -value ≤ 0.05; ** p -value ≤ 0.01; *** p -value ≤ 0.001; **** p -value ≤ 0.0001). H CFA quantification of VR and VR-RANO cells treated with DMSO (D) or ferrostatin-1 (ferro) or liproxstatin-1 (lipro). ( n = 4, Mean ± SEM, Holm-Sidák test of one-way ANOVA. **** p -value ≤ 0.0001). I, J Dose response curve for RSL3 in ( I ) VR and ( J ) VR_RANO cells in the presence or absence of 10 µM RANO.
Techniques Used: Expressing, Fluorescence, Imaging, Two Tailed Test
Figure Legend Snippet: A Quantification of differences in phospholipid levels between VR and VR_RANO cells. The median fold change ( p < 0.05, two-tailed unpaired t -test) from n = 4 peak area values between parental and VR and between VR and VR_R samples were assessed for up or down-regulation. PE phosphatidylethanolamine, PC phosphatidylcholine, LPC lysophosphatidylcholine, CL cardiolipin, PG phosphatidylglycerol, PS phosphatidylserine, PI phosphatidylinositol. B Heatmap of the indicated phosphatidylethanolamine (PE) or phosphatidylcholine (PC) levels in VR or VR_RANO cells. Peak area values were normalised to the average of the respective VR values. Only lipids with a median fold change between VR and VR_RANO cells with p ≤ 0.05 ( n = 4, two-tailed unpaired t -test) are shown. C Relative incorporation of MUFAs, PUFAs and saturated fatty acids (SFAs) into PE and PC in VR or VR_RANO cells considering the median fold change of peak area values (p ≤ 0.05, n = 4, two-tailed unpaired t -test). D , E Relative levels of the indicated ( D ) MUFAs and ( E ) PUFAs in A375, VR and VR_RANO cells; A375 cells were set 1. ( n = 4, Mea n ± SEM, Mean ± SD, Holm-Sidák test of 2-way ANOVA. ** p -value ≤ 0.01; *** p -value ≤ 0.001; **** p -value ≤ 0.0001). F , G Dose response curve for RSL3 in ( F ) VR and ( G ) VR_RANO cells in the presence or absence of 5 µM or 50 µM arachidonic acid (AA). H Schematic of the action of MBOAT1/2 in the Lands’ Cycle. I RT-qPCR for MBOAT1 and MBOAT2 in VR and VR_RANO cells. ( n = 6, Mea n ± SD, uncorrected Fisher’s LSD test of one-way ANOVA. **** p -value ≤ 0.0001). J CFA quantification of VR-RANO cells transfected with a control (sc) siRNA or siRNAs targeting MBOAT1 or MBOAT2. ( n = 6, Mea n ± SEM, Holm-Sidák test of one-way ANOVA). K Heatmap of CFA quantification of VR-RANO cells transfected as described and treated with the indicated concentrations of RSL3 or arachidonic acid (AA). ( n = 3, Mea n ± SEM, Mean ± SEM, Holm-Sidák test of 2-way ANOVA. * p -value ≤ 0.05; ** p -value ≤ 0.01; *** p -value ≤ 0.001; **** p -value ≤ 0.0001).
Techniques Used: Two Tailed Test, Quantitative RT-PCR, Transfection, Control
